Analysis of the associations of FC gamma receptor polymorphisms (FCGR3A, FCGR2A, and FCGR2B) with outcome in HER2+breast cancer patients treated with trastuzumab in NCCTG (Alliance) trial N9831

被引：0
|
作者：
Pegram, Mark [1 ]
Olson, Rebecca M. [1 ]
Norton, Nadine [2 ]
Tenner, Kathleen [3 ]
Ballman, Karla L. [3 ]
Clynes, Raphael [4 ]
Knutson, Keith L. [5 ]
Perez, Edith A. [2 ]
机构：
[1] Stanford Univ, Stanford, CA 94305 USA
[2] Mayo Clin, Jacksonville, FL 32224 USA
[3] Mayo Clin, Rochester, MN USA
[4] Columbia Univ, New York, NY USA
[5] Vaccine & Gene Therapy Inst, Port St Lucie, FL USA
来源：
MOLECULAR CANCER RESEARCH | 2013年 / 11卷
关键词：
D O I：
10.1158/1557-3125.ADVBC-B123
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B123
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Association Studies of Fcγ Receptor Polymorphisms with Outcome in HER2+ Breast Cancer Patients Treated with Trastuzumab in NCCTG (Alliance) Trial N9831
    Norton, Nadine
    Olson, Rebecca M.
    Pegram, Mark
    Tenner, Kathleen
    Ballman, Karla V.
    Clynes, Raphael
    Knutson, Keith L.
    Perez, Edith A.
    CANCER IMMUNOLOGY RESEARCH, 2014, 2 (10) : 962 - 969
  • [2] FCGR2A, FCGR3A, FCGR3B polymorphisms and susceptibility to rheumatoid arthritis: a meta-analysis
    Lee, Y. H.
    Bae, S. -C.
    Song, G. G.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2015, 33 (05) : 647 - 654
  • [3] Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/ HER2-Positive Breast Cancer Analysis of the NSABP B-31 Trial
    Gavin, Patrick G.
    Song, Nan
    Kim, S. Rim
    Lipchik, Corey
    Johnson, Nicole L.
    Bandos, Hanna
    Finnigan, Melanie
    Rastogi, Priya
    Fehrenbacher, Louis
    Mamounas, Eleftherios P.
    Swain, Sandra M.
    Wickerham, D. Lawrence
    Geyer, Charles E., Jr.
    Jeong, Jong-Hyeon
    Costantino, Joseph P.
    Wolmark, Norman
    Paik, Soonmyung
    Pogue-Geile, Kay L.
    JAMA ONCOLOGY, 2017, 3 (03) : 335 - 341
  • [4] IMPACT OF FCGR2A AND FCGR3A POLYMORPHISMS ON THE CLINICAL OUTCOME OF PATIENTS WITH METASTATIC COLORECTAL CANCER TREATED WITH CETUXIMAB AND FOLFIRI AS 2ND-LINE THERAPY
    Yuka, I.
    Hazama, S.
    Okayama, N.
    Hinoda, Y.
    Mishima, H.
    Sakamoto, J.
    Miyake, Y.
    Iwamoto, S.
    Goda, F.
    Oka, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 93 - 93
  • [5] Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms
    Ghesquieres, Herve
    Cartron, Guillaume
    Seymour, John Francis
    Delfau-Larue, Marie-Helene
    Offner, Fritz
    Soubeyran, Pierre
    Perrot, Aurore
    Brice, Pauline
    Bouabdallah, Reda
    Sonet, Anne
    Dupuis, Jehan
    Casasnovas, Olivier
    Catalano, John Vincent
    Delmer, Alain
    Jardin, Fabrice
    Verney, Aurelie
    Dartigues, Peggy
    Salles, Gilles
    BLOOD, 2012, 120 (13) : 2650 - 2657
  • [6] ABCB1, FCGR2A, and FCGR3A Polymorphisms in Patients with HER2-Positive Metastatic Breast Cancer Who Were Treated with First-Line Taxane plus Trastuzumab Chemotherapy
    Kim, Ji-Won
    Kim, Jee Hyun
    Im, Seock-Ah
    Kim, Yu Jung
    Han, Hye-Suk
    Kim, Jin-Soo
    Han, Sae-Won
    Jeon, Yoon Kyung
    Oh, Do-Youn
    Han, Wonshik
    Kim, Tae-You
    Park, In Ae
    Noh, Dong-Young
    Bang, Yung-Jue
    ONCOLOGY, 2012, 83 (04) : 218 - 227
  • [7] Functional Variants of Fc Gamma Receptor (FCGR2A) and FCGR3A Are Not Associated with Susceptibility to Systemic Sclerosis in a Large European Study (EUSTAR)
    Alizadeh, Behrooz Z.
    Broen, Jasper
    Rueda, Blanca
    Hesselstrand, Roger
    Wuttge, Dirk
    Simeon, Carmen
    Ortego-Centeno, Norberto
    Gonzalez-Gay, Miguel A.
    Pros, Anna
    Herrick, Ariane
    Worthington, Jane
    Denton, Christopher
    Fonseca, Carmen
    Riemekasten, Gabriela
    Vonk, Madelon C.
    Van den Hoogen, Frank
    Guiducci, Serena
    Matucci-Cerinic, Marco
    Scorza, Rafaella
    Beretta, Lorenzo
    Airo, Paolo
    Coenen, Marieke
    Martin, Javier
    Koeleman, Bobby P. C.
    Radstake, Timothy R. D. J.
    JOURNAL OF RHEUMATOLOGY, 2010, 37 (08) : 1673 - 1679
  • [8] The Influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab
    Magnes, T.
    Melchardt, T.
    Hufnagl, C.
    Weiss, L.
    Mittermair, C.
    Neureiter, D.
    Klieser, E.
    Rinnerthaler, G.
    Roesch, S.
    Gaggl, A.
    Greil, R.
    Egle, A.
    PHARMACOGENOMICS JOURNAL, 2018, 18 (03): : 474 - 479
  • [9] The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab
    T Magnes
    T Melchardt
    C Hufnagl
    L Weiss
    C Mittermair
    D Neureiter
    E Klieser
    G Rinnerthaler
    S Roesch
    A Gaggl
    R Greil
    A Egle
    The Pharmacogenomics Journal, 2018, 18 : 474 - 479
  • [10] Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS04 trial
    Lise Roca
    Véronique Diéras
    Henri Roché
    Emmanuelle Lappartient
    Pierre Kerbrat
    Laurent Cany
    Stéphanie Chieze
    Jean-Luc Canon
    Marc Spielmann
    Frédérique Penault-Llorca
    Anne-Laure Martin
    Christel Mesleard
    Jérôme Lemonnier
    Patricia de Cremoux
    Breast Cancer Research and Treatment, 2013, 139 : 789 - 800
12345